Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Langsted

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 25, 2017
Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in HumansSophie J Bernelot Moens, Simone L Verweij, Johan G Schnitzler, et al.
Clinical Chemistry|May 29, 2016
Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineBørge G Nordestgaard, Anne Langsted, Samia Mora, et al.
European Heart Journal|April 29, 2016
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineBørge G Nordestgaard, Anne Langsted, Samia Mora, et al.
Clinical Chemistry|May 16, 2018
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLMMichel R Langlois, M John Chapman, Christa Cobbaert, et al.
Clinical Chemistry and Laboratory Medicine|December 20, 2019
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLMMichel R Langlois, Børge G Nordestgaard, Anne Langsted, et al.
Atherosclerosis|January 14, 2020
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLMBørge G Nordestgaard, Michel R Langlois, Anne Langsted, et al.
JAMA Cardiology|June 22, 2018
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization AnalysisStephen Burgess, Brian A Ference, James R Staley, et al.
Nature Genetics|October 31, 2017
Exome-wide association study of plasma lipids in >300,000 individualsDajiang J Liu, Gina M Peloso, Haojie Yu, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 25, 2017
Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in HumansSophie J Bernelot Moens, Simone L Verweij, Johan G Schnitzler, et al.
Clinical Chemistry|May 29, 2016
Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineBørge G Nordestgaard, Anne Langsted, Samia Mora, et al.
European Heart Journal|April 29, 2016
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory MedicineBørge G Nordestgaard, Anne Langsted, Samia Mora, et al.
Clinical Chemistry|May 16, 2018
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLMMichel R Langlois, M John Chapman, Christa Cobbaert, et al.
Clinical Chemistry and Laboratory Medicine|December 20, 2019
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLMMichel R Langlois, Børge G Nordestgaard, Anne Langsted, et al.
Atherosclerosis|January 14, 2020
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLMBørge G Nordestgaard, Michel R Langlois, Anne Langsted, et al.
JAMA Cardiology|June 22, 2018
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization AnalysisStephen Burgess, Brian A Ference, James R Staley, et al.
Nature Genetics|October 31, 2017
Exome-wide association study of plasma lipids in >300,000 individualsDajiang J Liu, Gina M Peloso, Haojie Yu, et al.
Pageof 8